Targeted Therapies in Cancer

  • Manfred Dietel

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 176)

Table of contents

  1. Front Matter
    Pages I-XIV
  2. Prediction of Tumor Behavior

    1. Front Matter
      Pages 1-1
    2. Reinhold Schäfer, Anja Schramme, Oleg I. Tchernitsa, Christine Sers
      Pages 7-24
    3. Heinz Höfler, Rupert Langer, Katja Ott, Gisela Keller
      Pages 33-36
    4. Hermann Lage, Carsten Denkert
      Pages 51-60
    5. Hans Neubauer, Tanja Fehm, Christina Schütz, Runa Speer, Erich Solomayer, André Schrattenholz et al.
      Pages 89-120
  3. Targeted Therapy and Clinical Applications

    1. Front Matter
      Pages 121-121
    2. Agnieszka Korfel, Eckhard Thiel
      Pages 123-133
    3. Bert Hildebrandt, Philipp le Coutre, Annett Nicolaou, Konrad Kölble, Hanno Riess, Bernd Dörken
      Pages 135-143
    4. Jan Siehl, Eckhard Thiel
      Pages 145-151
    5. Ivana Zavrski, Christian Jakob, Martin Kaiser, Claudia Fleissner, Ulrike Heider, Orhan Sezer
      Pages 165-176
    6. Iver Petersen
      Pages 189-199
  4. Prospects for Development

    1. Front Matter
      Pages 211-211
    2. Ulrich Keilholz
      Pages 213-218
    3. Andreas Ziegler, Pierre G. Coulie, Barbara Uchańska-Ziegler
      Pages 229-241
    4. Utz Krug, Hubert Serve, Carsten Müller-Tidow, Rolf M. Mesters, Björn Steffen, Thomas Büchner et al.
      Pages 243-262

About this book


From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.

This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.

Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy.

This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.


Grading angiogenesis brain breast cancer cancer carcinoma cell chemotherapy hormones leukemia lymphoma melanoma metastasis targeted therapy tumor

Editors and affiliations

  • Manfred Dietel
    • 1
  1. 1.Institut für PathologieCharité Humboldt-Universität zu BerlinBerlinGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2007
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine Medicine (R0)
  • Print ISBN 978-3-540-46090-9
  • Online ISBN 978-3-540-46091-6
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology